BridgeBio Pharma, Inc. (BBIO)Healthcare | Biotechnology | Palo Alto, United States | NasdaqGS
63.30 USD
-2.45
(-3.726%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 63.00 -0.30 (-0.300%) ⇩ (Oct. 13, 2026, 5:04 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:20 a.m. EDT
The investment case for BridgeBio is currently paralyzed by a stark disconnect between its operational reality and its capital structure. Fundamentally, the company is bleeding cash with negative operating margins and a massive debt load of over $3.3 billion against only $720 million in cash. While the recent 148% price surge and strong revenue growth suggest a potential turnaround driven by pipeline milestones like Encaleret, the balance sheet remains a precarious liability that limits strategic flexibility. The market has priced in a premium despite these risks, yet the lack of a dividend and the absence of a fortress balance sheet prevent a 'buy and hold' thesis. From a technical perspective, the stock is trapped below its 50-day moving average, confirming the weakness. The options market is screaming caution, with traders aggressively buying deep out-of-the-money puts to protect against a collapse, while call buyers remain hesitant to commit capital beyond the immediate range. Until the debt burden is significantly reduced or a major catalyst forces a re-rating of the risk profile, the prudent stance is to wait for clarity rather than chase the momentum. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.094529 |
| AutoARIMA | 0.094952 |
| AutoETS | 0.097068 |
| AutoTheta | 0.178381 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 91.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.109 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.675 |
| Market Cap | 12,374,706,176 |
| Forward P/E | 2190.31 |
| Beta | 0.97 |
| Profit Margins | -97.03% |
| Website | https://bridgebio.com |
As of Oct. 10, 2026, 7:20 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume (over 10k contracts) expiring in January 2027, creating a massive 'floor' around the $45 strike. This suggests a fear of a significant downside event or a prolonged grind lower. Conversely, call interest is concentrated near the money ($65-$75 strikes) with moderate open interest, indicating a belief that the stock will trade sideways or attempt a modest recovery rather than a explosive breakout. The implied volatility surface shows elevated premiums for deep out-of-the-money puts relative to calls, reinforcing a bearish skew.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.1637168 |
| Address1 | 3,160 Porter Drive |
| Address2 | Suite 250 |
| All Time High | 93.415 |
| All Time Low | 4.98 |
| Ask | 68.52 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 2,754,550 |
| Average Daily Volume3 Month | 2,388,015 |
| Average Volume | 2,388,015 |
| Average Volume10Days | 2,754,550 |
| Beta | 0.972 |
| Bid | 59.97 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -12.88 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 63.3 |
| Current Ratio | 1.227 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 66.05 |
| Day Low | 62.94 |
| Display Name | BridgeBio Pharma |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,392,000 |
| Earnings Call Timestamp Start | 1,786,392,000 |
| Earnings Timestamp | 1,786,392,000 |
| Earnings Timestamp End | 1,793,217,600 |
| Earnings Timestamp Start | 1,793,217,600 |
| Ebitda | -472,752,000 |
| Ebitda Margins | -0.66297996 |
| Enterprise To Ebitda | -31.807 |
| Enterprise To Revenue | 21.087 |
| Enterprise Value | 15,036,668,928 |
| Eps Current Year | -2.58425 |
| Eps Forward | 0.0289 |
| Eps Trailing Twelve Months | -3.56 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 74.2458 |
| Fifty Day Average Change | -10.945797 |
| Fifty Day Average Change Percent | -0.14742649 |
| Fifty Two Week Change Percent | 16.37168 |
| Fifty Two Week High | 93.415 |
| Fifty Two Week High Change | -30.115002 |
| Fifty Two Week High Change Percent | -0.32237864 |
| Fifty Two Week Low | 52.75 |
| Fifty Two Week Low Change | 10.549999 |
| Fifty Two Week Low Change Percent | 0.19999999 |
| Fifty Two Week Range | 52.75 - 93.415 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,642,200,000 |
| Float Shares | 167,175,023 |
| Forward Eps | 0.0289 |
| Forward P E | 2,190.3115 |
| Free Cashflow | -320,264,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 999 |
| Fullday Change | -2.75 |
| Fullday Change Percent | -4.1825094 |
| Fullday Price | 63.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.94439006 |
| Gross Profits | 673,414,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03912 |
| Held Percent Institutions | 0.99552 |
| Implied Shares Outstanding | 195,492,997 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. |
| Long Name | BridgeBio Pharma, Inc. |
| Market | us_market |
| Market Cap | 12,374,706,176 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_412911458 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -691,865,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,847,799,762 |
| Number Of Analyst Opinions | 21 |
| Open | 66.05 |
| Operating Cashflow | -434,374,016 |
| Operating Margins | -0.43943 |
| Overall Risk | 8 |
| Phone | 650 391 9740 |
| Post Market Change | -0.29999924 |
| Post Market Change Percent | -0.47393245 |
| Post Market Price | 63.0 |
| Post Market Time | 1,791,925,477 |
| Previous Close | 65.75 |
| Price Eps Current Year | -24.494534 |
| Price Hint | 2 |
| Price To Book | -4.914596 |
| Price To Sales Trailing12 Months | 17.35415 |
| Profit Margins | -0.97026 |
| Quick Ratio | 1.094 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.45455 |
| Region | US |
| Regular Market Change | -2.4500008 |
| Regular Market Change Percent | -3.7262368 |
| Regular Market Day High | 66.05 |
| Regular Market Day Low | 62.94 |
| Regular Market Day Range | 62.94 - 66.05 |
| Regular Market Open | 66.05 |
| Regular Market Previous Close | 65.75 |
| Regular Market Price | 63.3 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 2,708,427 |
| Return On Assets | -0.25997 |
| Revenue Growth | 1.204 |
| Revenue Per Share | 3.675 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 195,492,997 |
| Shares Percent Shares Out | 0.100600004 |
| Shares Short | 19,671,292 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 21,845,899 |
| Short Name | BridgeBio Pharma, Inc. |
| Short Percent Of Float | 0.112399995 |
| Short Ratio | 7.16 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBIO |
| Target High Price | 156.0 |
| Target Low Price | 80.0 |
| Target Mean Price | 109.04762 |
| Target Median Price | 110.0 |
| Total Cash | 720,160,000 |
| Total Cash Per Share | 3.684 |
| Total Debt | 3,373,149,952 |
| Total Revenue | 713,068,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 73.2888 |
| Two Hundred Day Average Change | -9.988804 |
| Two Hundred Day Average Change Percent | -0.13629372 |
| Type Disp | Equity |
| Volume | 2,708,427 |
| Website | https://bridgebio.com |
| Zip | 94,304 |